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osting by EAbstract A series of thiosemicarbazones of aromatic iodide derivatives were designed and synthe-
sized. The structures of all the newly synthesized compounds had been identiﬁed by elemental anal-
ysis, 1H NMR and 13C NMR. Their biological activities were evaluated against Plasmodium
falciparum. Among these compounds, at concentrations of 3, 9 and 27 mg/kg of mouse per day,
4e inhibited the growth of the malaria parasite in vivo test in mice with the respective percentages:
88.1%, 90.7% and 92.6%. The present work suggest that thiosemicarbazones of aromatic iodide
may become a lead compound for anti-malaria medicine.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Malaria is one of the most signiﬁcant infectious diseases in the
world. It is endemic through the entire tropical region of the
Earth, except for high mountain areas, deserts and a few
islands (Cox-singh et al., 2008; Guinovart et al., 2006; Plowe,
2005; Newman et al., 2004; Leder et al., 2006). Chloroquine
has been themost effective andwidely used drug inmalaria ther-
apy. Therefore, great hopes have been placed on development of164377008.
il.com (H.B. Zhang).
y. Production and hosting by
Saud University.
lsevieragents, which can reverse resistance to chloroquine (Uhlemann
and Krishna, 2005; Nogueira et al., 2010). Recently there were
a lotof studiesusing iron-chelatingagents asapossible treatment
for malaria (Cabantchik, 1994; Kontoghiorghes et al., 2010).
Thiosemicarbazones are known iron-chelating agents by bond-
ing through the sulfurandazomethinenitrogenatoms (Walcourt
et al., 2004). Their activity against extracellular protozoan such
as Plasmodiumfalciparum, Trichomonas vaginalis, Trypanosoma
cruzi, and other parasites were demonstrated by several works
(Greenbaum et al., 2004; Bharti et al., 2002).
On the other hand, iodine is a trace mineral required for hu-
man life. Iodine is important in the developing of the fetus,
particularly in the brain. It helps the functioning of the heart,
pancreas, liver, kidneys, muscles, and brain. Iodine promotes
general growth and development of the body as well as metab-
olism of nutrients (Azuolas and Caple, 1984; Lamard and
Tressol, 1989; Boyages, 1993). The replacement of chlorine
atom by iodine atom led to compounds with a less toxicity
and better biology activity. These prompted us to explore the
biological activities of thiosemicarbazone analogs of aromatic
iodide. In this context, we report the preparation of new thio-
232 L.P. Duan, H.B. Zhangsemicarbazones of aromatic iodide analog. These compounds
were tested in vivo for their ability to inhibit the growth of ma-
laria parasite.
2. Experimental
2.1. Material and reagents
All the reagents and solvents were of the commercial quality
and were used without puriﬁcation. Elemental analysis was
performed on a PE-2400 elemental analyzer, the C, H and N
analysis were repeated twice. 1H NMR and 13C NMR spectra
were obtained with a Bruker AM-400 spectrometer with chem-
ical shifts reported as ppm (in DMSO-d6, TMS as internal
standard). Melting points were determined by an X-6 micro-
melting point apparatus and were uncorrected.
2.2. General procedure for the preparation of 4-(p-iodophenyl)-
3-thiosemicarbazone derivatives (4a–4e)
The synthetic routes of the target compounds 4a–4e were
shown in Scheme 1. In a typical procedure (Hodgkins and
Reeves, 1964). Aromatic iodine 1 (21.9 g, 0.1 mol) was dis-
solved in the minimum amount of benzene and treated with
7.0 mL of carbon disulﬁde and 16 mL of triethylamine in ice
bath, then the solution ﬁltered to get the solid, which was then
dissolved in 90 mL of chloroform. A mixture of 15 mL of tri-
ethylamine and 10.2 mL of ethyl chlorocarbonate was added
dropwise, followed by stirring for 1 h. The chloroform solution
was washed with 3 mol L1 HCl and water, respectively, and
dried over sodium sulfate, then evaporated in vacuum to dry-
ness to get crude solid, which on recrystallization with ethanol
gave 2. Compound 2 (26.1 g, 0.1 mol) was dissolved in mini-
mum amount of ethanol, and then was dropped to hydrazine
hydrate (24 g, 0.4 mol) at ambient temperature. A white solid
was separated, which was washed and dried to give 3. Equimo-
lar quantities of thiosemicarbazones 3 and difference aldehydes
were mixed in boiling ethanol for about 1–2 h, then solution
was concentrated, the solid was ﬁltered and recrystallized with
ethanol and dried to give 4a–4e.
All the target compounds were pale yellow solid and stable
at room temperature, insoluble in water and readily soluble in
DMF and DMSO.5e:
NH2
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Scheme 1 The synthetic route2.2.1. Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone
(4a)
Yield 87%, m.p. 191–192 C; 1H NMR (DMSO-d6, 400 MHz)
d: 11.71 (s, 1H, NH), 9.97 (s, 1H, NH), 9.91 (s, 1H, OH), 8.07
(s, 1H, CH‚N), 7.73–6.80 (m, 8H, Ar-H); 13C NMR (DMSO-
d6, 100 MHz) d: 170.24, 140.18, 139.19, 134.62, 133.95, 126.41,
124.70, 113.63, 112.27, 109.28, 105.78, 103.44, 103.27, 90.29;
Anal. calcd for C14H12IN3OS (397.2): C 42.33, H 3.04, N
10.58; found C 42.56, H 3.04, N 10.68.
2.2.2. Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone
(4b)
Yield 90%, m.p. 202–203 C; 1H NMR (DMSO-d6, 400 MHz)
d: 11.63 (s, 1H, NH), 9.91 (s, 1H, NH), 8.04 (s, 1H, CH‚N),
7.68–6.73 (m, 8H, Ar-H), 2.97 (s, 6H, N(CH3)2);
13C NMR
(DMSO-d6, 100 MHz) d: 175.20, 149.21, 147.83, 142.89,
138.89, 137.77, 128.82, 126.18, 123.52, 123.49, 117.35, 112.30,
89.37, 40.94; Anal. calcd for C16H17IN4S (424.3): C 45.29, H
4.04, N 13.20; found C 45.34, H 4.14, N 13.18.
2.2.3. Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone
(4c)
Yield 82%, m.p. 195–196 C; 1H NMR (DMSO-d6, 400 MHz)
d: 11.73 (s, 1H, NH), 9.97 (s, 1H, NH), 9.51 (s, 1H, OH),8.06
(s, 1H, CH‚N), 7.71–6.80 (m, 8H, Ar-H), 3.83 (s, 3H, OCH3);
13C NMR (DMSO-d6, 100 MHz) d: 175.18, 149.10, 147.94,
143.88, 139.04, 136.66, 127.81, 125.16, 122.50, 122.48, 115.33,
110.29, 89.64, 55.83; Anal. calcd for C15H14IN3O2S (427.2):
C 42.17, H 3.30, N 9.83; found C 42.10, H 3.37, N 9.96.
2.2.4. Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone
(4d)
Yield 88%, m.p. 175–176 C; 1H NMR (DMSO-d6, 400 MHz)
d: 11.63 (s, 1H, NH), 10.17 (s, 1H, NH), 9.94 (s, 1H, OH), 9.83
(s, 1H, OH), 8.36 (s, 1H, CH‚N), 7.85–6.39 (m, 8H, Ar-H);
13C NMR (DMSO-d6, 100 MHz) d: 168.04, 139.16, 137.09,
136.60, 132.90, 127.40, 125.69, 111.62, 110.26, 108.18, 107.75,
102.44, 102.24, 89.29; Anal. calcd for C14H12IN3O2S (413.2):
C 40.69, H 2.93, N 10.17; found C 41.00, H 3.08, N 9.98.
2.2.5. Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone (4e)
Yield 85%, m.p. 201–202 C; 1H NMR (DMSO-d6, 400 MHz)
d: 11.78 (s, 1H, NH), 10.07 (s, 1H, NH), 8.06 (s, 1H, CH‚N),NHCNHNH2
I
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13C NMR
(DMSO-d6, 100 MHz) d: 175.50, 149.09, 148.02,
138.98,138.81, 136.63, 135.14, 128.41, 128.03, 127.32, 124.36,
108.13, 105.58, 101.45, 89.80; Anal. calcd for C15H12IN3O2S
(425.2): C 42.37, H 2.84, N 9.88; found C 42.13, H 2.74, N 9.91.
2.3. In vivo in mice anti-malarial study
The biology activities of the target compounds were evaluated
against malaria parasite according with the standard test pro-
cedures (WHO standard).
3. Results and discussion
3.1. Synthesis of 4-(p-iodophenyl)-3-thiosemicarbazone
derivatives and characterization
Firstly, aromatic iodine 1 was treated with carbon disulﬁde
and chloroform to obtain isothiocyanate 2, and coupling reac-
tions with hydrazine hydrate to give thiosemicarbazones 3.
Then the title compounds 4a–4e were successfully obtained
using difference aldehydes as reagent. Compounds 4a–4e were
characterized by 1H NMR, 13C NMR and elemental analysis.
All results are in full agreement with the proposed structures.
For example, the singlet signal at 8.06 ppm (CH‚N) and
the signal at 6.08 ppm (OCH2O) of
1H NMR spectra suggest
that compound 4e is consistent with its structure. The results
of elemental analyses are in good agreement with those calcu-
lated for the suggested formula. The melting points are sharp
indicating the purity of these compounds.
3.2. Anti-malarial activity
The biology activities of the target compounds were evaluated
against malaria according to the standard bioactivity test pro-Table 1 The inhibition percentage of the target compounds
against Plasmodium falciparum.
Compound Concentrations
(mg/kg)
Percentages
of suppression
of Plasmodium
falciparum
4-(p-Iodophenyl)-
3-thiosemicarbazone (4a)
3 60.2
9 78.2
27 80.0
4-(p-Iodophenyl)-
3-thiosemicarbazone (4b)
3 54.3
9 60.2
27 65.3
4-(p-Iodophenyl)-
3-thiosemicarbazone (4c)
3 62.3
9 79.1
27 80.2
4-(p-Iodophenyl)-
3-thiosemicarbazone (4d)
3 64.3
9 80.4
27 82.1
4-(p-Iodophenyl)-
3-thiosemicarbazone (4e)
3 88.1
9 90.7
27 92.6
4-(p-Chlorophenyl)-
3-thiosemicarbazone (5e)
3 58.0
9 74.8
27 77.0
Chloroquine (3 mg/kg of mouse, positive control) had a suppressive
activity of 100%.cedures (WHO standard). The results were summarized in
Table 1. From Table 1, we could ﬁnd that these compounds
showed signiﬁcant anti-malarial activities in the four-day sup-
pressive in vivo test in mice. At concentrations of 3, 9 and
27 mg/kg of mouse per day, in contrast, compound 4e pro-
duced the highest activity against malaria. For anti-malarial
activity, structural variation between compounds 4a and 4b re-
sults in remarkably different activity. The only structural dif-
ferences between 4a and 4b are the types of substituents at
C-10. Compound 4a contain hydroxyl group moiety at C-10,
while 4b has a N(CH3)2 group moiety at C-10. This hydroxyl
group appears to be particularly responsible for anti-malarial
activity. Compounds 4a, 4c and 4d, which contain hydroxyl
group moiety at C-10, while 5 has 1,3-dioxolane ring on C-9/
C-10 seemed to be much more effective in terms of anti-malar-
ial activity. Furthermore, Compound 4e inhibited the growth
of the malaria parasite with the respective percentages:
88.1%, 90.7% and 92.6%. The corresponding values for 5e
at the same concentrations were 58.0%, 74.8% and 77.0%,
respectively. It was worth noting that the thiosemicarbazones
of aromatic iodide analog showed improved biology activities
to some extent over aromatic chloride counterparts against
malaria, which might be contributed by the introduction of io-
dine atom in benzene.
4. Conclusions
In summary, various types of thiosemicarbazones of aromatic
iodide were synthesized and their varying biology activities to-
wards the malaria was demonstrated. The present work sug-
gest that thiosemicarbazones of aromatic iodide may become
a lead compound for anti-malaria medicine. Further struc-
ture–biology activity relationships about the designed com-
pounds were under the way.Acknowledgements
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